Shots:

• The P-Ia/Ib study evaluating cadonilimab (PD-1/CTLA-4 bispecific Ab) in patients with advanced solid tumors
• The results showed that cadonilimab reached a dose of 25mg/kg, q3w without encountering the MTD, occurrence of sev. irAE with a grade of ≥3 was 6.7%. The treatment showed a favorable safety & tolerability profile, and tumor response was seen in PD-L1+ and PD-L1-solid tumor populations indicating unique efficacy advantages over PD-1/PD-L1 mAb & may have a broader range of potential indications
• The therapy was found to have a favorable toxicity profile with promising efficacy. Cadonilimab is a bispecific Ab targeting PD-1 & CTLA-4. The company has conducted a series of 60+ clinical studies globally for solid tumors

Ref: PRNewswire  | Image: Akeso

Related News:- Akeso Reports the First Patient Dosing of Ivonescimab in P-III Trial as 1L Treatment of Squamous Non-Small Cell Lung Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com